KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 25 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $7,383,000 | +50.8% | 388,766 | 0.0% | 0.92% | -34.7% |
| Q3 2020 | $4,895,000 | +4.1% | 388,766 | 0.0% | 1.41% | -63.8% |
| Q2 2020 | $4,704,000 | +58.2% | 388,766 | 0.0% | 3.90% | +24.2% |
| Q1 2020 | $2,974,000 | -57.0% | 388,766 | 0.0% | 3.14% | +5.3% |
| Q4 2019 | $6,924,000 | +53.5% | 388,766 | 0.0% | 2.98% | +72.4% |
| Q3 2019 | $4,510,000 | -47.6% | 388,766 | 0.0% | 1.73% | -37.8% |
| Q2 2019 | $8,611,000 | -22.6% | 388,766 | 0.0% | 2.78% | -72.8% |
| Q1 2019 | $11,126,000 | +44.9% | 388,766 | 0.0% | 10.22% | -5.2% |
| Q4 2018 | $7,678,000 | -10.7% | 388,766 | 0.0% | 10.78% | +156.8% |
| Q3 2018 | $8,596,000 | +220.9% | 388,766 | +17.8% | 4.20% | +270.8% |
| Q2 2018 | $2,679,000 | -14.4% | 329,942 | 0.0% | 1.13% | -14.1% |
| Q1 2018 | $3,128,000 | -2.8% | 329,942 | 0.0% | 1.32% | +19.8% |
| Q4 2017 | $3,217,000 | +44.8% | 329,942 | 0.0% | 1.10% | +90.3% |
| Q3 2017 | $2,221,000 | -8.5% | 329,942 | 0.0% | 0.58% | +0.5% |
| Q2 2017 | $2,428,000 | -5.8% | 329,942 | 0.0% | 0.58% | +4.9% |
| Q1 2017 | $2,577,000 | +10.5% | 329,942 | 0.0% | 0.55% | -1.4% |
| Q4 2016 | $2,333,000 | – | 329,942 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |